key: cord-0943431-eey3j1uk
authors: Chen, C.; Nadeau, S. A.; Topolsky, I.; Manceau, M.; Huisman, J. S.; Jablonski, K. P.; Fuhrmann, L.; Dreifuss, D.; Jahn, K.; Beckmann, C.; Redondo, M.; Kobel, O.; Noppen, C.; Risch, L.; Risch, M.; Wohlwend, N.; Kas, S.; Bodmer, T.; Roloff, T.; Stange, M.; Egli, A.; Eckerle, I.; Denes, R.; Feldkamp, M.; Nissen, I.; Santacroce, N.; Burcklen, E.; Aquino, C.; de Gouvea, A. C.; Moccia, M. D.; Gruter, S.; Sykes, T.; Opitz, L.; White, G.; Neff, L.; Popovic, D.; Patrignani, A.; Tracy, J.; Schlapbach, R.; Dermitzakis, E. T.; Harshman, K.; Xenarios, I.; Pegeot, H.; Cerutti, L.; Penet, D.; Blin, A.; Elies,
title: Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland
date: 2021-03-09
journal: nan
DOI: 10.1101/2021.03.05.21252520
sha: 6983bdfc1d8c5b770b7f5a19b82ce40c230c146f
doc_id: 943431
cord_uid: eey3j1uk

In December 2020, the United Kingdom (UK) reported a SARS-CoV-2 Variant of Concern (VoC) which is now coined B.1.1.7. Based on the UK data and later additional data from other countries, a transmission advantage of around 40-80% was estimated for this variant. In Switzerland, since spring 2020, we perform whole genome sequencing of SARS-CoV-2 samples obtained from a large diagnostic lab (Viollier AG) on a weekly basis for genomic surveillance. The lab processes SARS-CoV-2 samples from across Switzerland. Based on a total of 7631 sequences obtained from samples collected between 14.12.2020 and 11.02.2021 at Viollier AG, we determine the relative proportion of the B.1.1.7 variant on a daily basis. In addition, we use data from a second lab (Dr Risch) screening all their samples for the B.1.1.7 variant. These two datasets represent 11.5 % of all SARS-CoV-2 confirmed cases across Switzerland during the considered time period. They allow us to quantify the transmission advantage of the B.1.1.7 variant on a national and a regional scale. Taking all our data and estimates together, we propose a transmission advantage of 49-65% of B.1.1.7 compared to the other circulating variants. Further, we estimate the effective reproductive number through time for B.1.1.7 and the other variants, again pointing to a higher transmission rate of B.1.1.7. In particular, for the time period 01.01.2021-17.01.2021, we estimate an average reproductive number for B.1.1.7 of 1.28 [1.07-1.49] while the estimate for the other variants is 0.83 [0.63-1.03], based on the total number of confirmed cases and our Viollier sequencing data. Switzerland tightened measures on 18.01.2021. A comparison of the empirically confirmed case numbers up to 20.02.2021 to a very simple model using the estimates of the reproductive number from the first half of January provides indication that the rate of spread of all variants slowed down recently. In summary, the dynamics of increase in frequency of B.1.1.7 is as expected based on the observations in the UK. Our plots are available online and constantly updated with new data to closely monitor the changes in absolute numbers.

Reports of an increased transmissibility of SARS-CoV-2 variant B.1.1.7 (501Y.V1) were released in mid-December 2020 [4, 5, 6] . This variant carries the N501Y mutation in the spike protein which may increase the ACE2 receptor affinity [7] . Within only a few months, the variant was able to become the dominant lineage in the UK.

Since these first reports, great efforts were made in Switzerland to detect and trace B.1.1.7 [8] .

The first cases of B.1.1.7 were confirmed on 24.12.2020 and retrospective analyses identified B.1. 1.7 in samples dating back to October [8] . In total, 1370 infections with B.1.1.7 were confirmed up to 05.02.2021 [8] .

An increase in prevalence does not necessarily imply a transmission fitness advantage of the virus.

For example, a variant termed 20A.EU1 spread rapidly during summer 2020 across Europe. However, data suggests that extended travel and superspreading events rather than a viral transmission advantage caused that spread [9] .

However, the variant B.1.1.7 rapidly increased in frequency in many high-prevalence regions across the UK. Such re-occuring patterns are hard to explain without a transmission advantage. Analyses of the B.1.1.7 variant in the UK suggest that the variant has a transmission fitness advantage anywhere between 40 and 80% [1, 2, 3] . Davies et al [3] further uses data from Denmark obtaining again similar estimates. Quantitative analysis of data on the spread of the 501Y mutation in Switzerland also suggests a transmission advantage in roughly that range [10] .

In this paper, we collected whole genome sequencing data based on samples from Viollier AG The core plots presented here will be updated regularly on [11] and part of it is currently incorporated into the Swiss National COVID-19 Science Task Force website [12] . The code and data used for this paper is publically available on Github [13] . All sequences based on samples fro Viollier are available on GISAID. 3 

The main source of data are whole genome sequences based on samples from Viollier AG. Viollier AG is a large diagnostic lab processing SARS-CoV-2 samples from across Switzerland. Every week, SARS-CoV-2 samples were randomly selected for sequencing among all positively tested samples at the Viollier AG. For each sample, we know the date of the test and the canton in which the test was performed.

We perform whole genome sequencing in three facilities. The sequencing protocol for the samples sequenced at the Genomics Facility Basel and the Functional Genomics Center Zurich is described in [14] . Samples processed at the Health 2030 Genome Center used the Illumina COVIDSeq library preparation reagents following the protocol provided by the supplier [15] . These reagents are based on the ARTIC v3 multiplex PCR amplicon protocol [16] . When sufficient volume was available, 8.5ul of RNA extracted from patient nasopharyngeal samples were used in the cDNA synthesis step; if 8.5ul were not available, the maximum volume possible was used. Pooled libraries were sequenced on the Illumina NovaSeq 6000 using a 50-nucleotide pair-end run configuration. Post-sequencing library read de-multiplexing was done using an in-house developed processing pipeline [17] .

The downstream bioinformatics procedure to obtain consensus sequences is described in [14, 18] .

In the time frame of interest -from 14.12.2020 to 11.02.2021, a total of 7631 sequences were generated and checked for the B.1.1.7 variant. Thus, per week we produced around 900 sequences. In the same time period, 154'241 people were confirmed with a SARS-CoV-2 infection, thus we provide sequences for 4.9% of all cases. We define a sequence to be a B.1.1.7 sample if at least 80% of the lineage-defining, non-synonymous nucleotide changes according to [4] ten times more samples were sequenced from the region Nordwestschweiz than from the region Ticino (Table 1) . Dr Risch's data has a different geographic distribution than Viollier and, for example, a much better coverage of Eastern Switzerland. In summary, both datasets differ in their geographic biases. We present results on the different datasets and compare these results.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

In what follows, we define two models describing the dynamics with which a new variant with a transmission fitness advantage spreads in a population. The first model is based on the assumption of discrete time, while the second model is based on the assumption of continuous time. Both models have been considered extensively in the literature to estimate fitness advantage (see e.g. [20, 3] ). While in an epidemic, a generation does not end after a fixed time span (discrete time model), generations are typically less variable than modelled under an exponential distribution (continuous time model).

Thus we view the two models as two extremes with the actual dynamics being described by a process in between. We provide estimates based on both models and suggest that the true parameter may be anywhere within the ranges spanned by the two models. In the next sections, we provide details of how we estimate the transmission fitness advantage of B.1.1.7 based on daily data of the total number of samples and B.1.1.7 samples under these two models.

We call X the common (non-B. Thus, we assume a multiplicative fitness advantage.

We have x(n) = x(0)×R d (0)R d (1) . . . R d (n−1) and y(n) = y(0)

If R d is constant through time, we have 6 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 9, 2021. x(n) = x(0)R n d and y(n) = y(0)(

Let the proportion of variant Y at generation n be p(n). We have,

.

Thus, p(n) is the logistic function. It does not depend on R d .

If we write time in days t rather than generations n and assume a generation time of g days, we

get

We now switch our parameterization to the more common

for parameter estimation from daily data. Parameter a is the logistic growth rate and parameter t 0 the sigmoid's midpoint.

The two free parameters, a and t 0 , are related to the two free parameters in Equation 1, f d and p(0), as follows:

In particular, we get f d = e ag − 1.

7 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.05.21252520 doi: medRxiv preprint

In continuous time, instead of R d and generation time g, we define the transmission rate β and the recovery rate µ. Under this model, the reproductive number is R c = β/µ. Further, since an individual in the discrete model recovers after a generation of duration g (during which they left R d offspring), we note that g is related to the expected time to recovery 1/µ in the continuous model, and in fact assume g = 1/µ in what follows. Again our initial numbers of the variants X and Y are x(0) and y(0). Calendar time is denoted by a continuous parameter t. We then have in expectation,

We note that β − µ is coined the Malthusian growth parameter [3] .

Further we again assume that variant Y has a transmission fitness advantage of f c , with transmission rate β(1 + f c ) and recovery rate µ. The population size of the variant at time t is thus

The proportion of the variant in the population at time t is

where we again recognize the logistic function. We turn again to the more common parameterization,

where we thus have f c = a β . The reproductive number is R c = β/µ and the mean time to recovery, 1/µ, is equaled to g. Then,

CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 9, 2021.

In particular, we have f c = ag Rc . Note that the estimated fitness advantage under this model depends on the reproductive number R c and is thus changing if R c is changing through time.

The discrete and continuous models are very similar. Both have the intitial conditions x(0) and y(0). For the dynamics, the discrete model has parameters R d and g while the continuous model has parameters β and µ. We have R c = β/µ and we further assumed that g = 1/µ (1/µ is the expected time until recovery in the continuous setting while g is the time to recovery in the discrete setting).

The different parameterizations of fitness advantage are coined f c and f d . We now determine how f c and f d are related.

To compare the two models, we now assume that their overall dynamics for the variant X are the same. After n generations of duration g, we have for variant X,

Using a Taylor expansion for β/µ close to 1, we obtain that indeed R d = R c .

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.05.21252520 doi: medRxiv preprint For the two models to produce the same growth also for variant Y , we require,

In the last step, we make use of R c = β/µ and g = 1/µ.

This is equivalent to f d = e Rcfc −1. Using a Taylor expansion we get

Next we explain how we estimate a and t 0 of the logistic functions (Eqn. 2 and 5) from our data using maximum likelihood. We consider that we have data at times t 1 , ..., t d . At time t i , we obtained n i samples, where n i is fixed, non-random.

We assume that the true number of B.1.1.7 variants at time t i is a random variable, K i which is binomially distributed with parameter p(t i ), i.e.

In particular we assume here a deterministic logistic growth model for the increase in the proportion of variant Y (Eqn. 2 and 5), on top of which only the drawing process is random. This model simplifies naturally to a very popular logistic regression. This is an instance of a Generalized Linear Model, where the natural parameter of the binomial distribution is a linear function of predictors, the only predictor considered here being the time t.

We use the Python library statsmodel [21] to recover maximum likelihood estimates (MLEs) and confidence intervals based on an asymptotic Gaussian distribution for the parameters of the logistic regression based on our data, i.e. the fixed values t 1 , . . . , t d , n 1 , . . . , n d as well as the numbers of 10 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Gaussian, with a covariance matrix found by applying the delta method. This is used to construct confidence intervals for all these quantities.

We use the number of confirmed cases per day from the Federal Office of Public Health, Switzerland, for 14.12.2020 to 11.02.2021. Then, for each day, we estimate the number of B.1.1.7 variants by multiplying the total number of confirmed cases by the proportion of B.1.1.7 in our dataset (Viollier or Risch). We then estimate an effective reproductive number of the B.1.1.7 variant and of the non-B.1.1.7 variants using these data. For this estimation, we use the method developed in [22] . This method consists of two main parts: first, the observed case data is related to the corresponding time series of infections. We smooth the observations using LOESS smoothing to remove weekend effects.

Then, we deconvolve with the delay of infection to symptom onset (gamma distributed with mean 5.3 and sd 3.2) and the delay from symptom onset to case confirmation (gamma distributed with mean 5.5 and sd 3.8). Second, we estimate the effective reproductive number from the time series of infection incidence using EpiEstim [23] . The reported point estimate is the estimate on the original case data. To account for uncertainty in the observation process, the observed daily case incidences are additionally bootstrapped 1000 times, resulting in an ensemble of alternative case incidence time series and corresponding estimated effective reproductive numbers. These are used to construct the 95% confidence interval around the effective reproductive number, and to calculate the standard deviation of the ratios of effective reproductive number estimates (see below).

We perform the estimation of the reproductive number in two different ways. First, we estimate smooth changes in the reproductive number, by estimating it across the entire time series using a 3day sliding window. Second, we assume the reproductive number was constant during time intervals in which the non-pharmaceutical interventions did not change. Since 18.01.2021, Switzerland has implemented a set of tighter measures (in particular, shops are closed and the size of gatherings is restricted to five people [24] ). Thus we fix the reproductive number to be constant between 01.01.2021 11 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. variants (X), we take the ratio ρ = R Y R X at every time point. The standard deviation of this ratio σ ρ was found through Gaussian error propagation of the standard deviation of the individual R estimates (σ X , σ Y ): (Table   3 ).

We estimate the logistic growth rate a and the sigmoid's midpoint t 0 based on the Viollier and Risch data ( In Fig. 1 and 2 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.05.21252520 doi: medRxiv preprint (parameter p(t i ) on each day t i ).

Next, we estimate the reproductive number for B.1.1.7 and non-B.1.1.7 on a national scale (Fig. 3) Table 3 . On a national level, we estimate a fitness advantage of 49-65% across methods and datasets. The regional estimates have an overlap with this interval.

We note that we use the national reproductive number for the regional f c estimate. Since Ticino had a lower and the Lake Geneva region a higher reproductive number averaged over all variants [25] , the f c for Ticino may be an underestimate and the f c for Geneva an overestimate. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.05.21252520 doi: medRxiv preprint B.1.1.7 becomes dominant, the total number of cases will be increasing again. It is important to note that this simple model assumes that the transmission dynamics do not change and in particular does not include the effects of vaccination, immunity after infection, and population heterogeneity. The discrepancy for Ticino and Lake Geneva is not surprising: they had a reproductive number which was different from the national reproductive number in the first half of January. For Ticino, the empirical case numbers drop faster than the model, which is in line with a lower reported reproductive number compared to the national level. For the Lake Geneva region, the empirical case numbers drop slower than the model, which is in line with a higher reported reproductive number compared to the national level [25] . For all regions but Ticino, we have enough data to estimate a reproductive number for the non-B.1.1.7 variants for 01.01.2021-17.01.2021. While for Switzerland, we obtained a point estimate of 0.83, the point estimates for all regions but Lake Geneva are between 0.81-0.83. Thus using the point estimate for all of Switzerland for the regional plots in Fig. 5 is justified. For Geneva, we obtain a point estimate of 0.88. We use this point estimate estimate in a Lake Geneva specific model (Fig. 6) . Again we observe that the total number of confirmed cases dropped recently faster compared to the model. 14 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 9, 2021. ;

Region 15 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Fig. 4 . We use the reproductive number estimated for the whole of Switzerland for the continuous time model such that we can compare to what extend regions differ from the national dynamic. The regional transmission fitness advantage is taken from Table 3. 19 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.05.21252520 doi: medRxiv preprint

We have quantified the transmission fitness advantage of B.1.1.7 for two Swiss datasets. One dataset also allows us to obtain estimates for the seven Swiss economic regions. Swiss-wide estimates point towards a transmission fitness advantage of 49-65%. Our estimates predict that in March, B.1.1.7 will be dominant in Switzerland. This is in line with predictions by [10] Our data reveals that different regions from Switzerland were sampled with different intensity.

Thus, we also performed analyses for the seven economic regions in Switzerland. Here, we expect that the homogeneous sampling intensity is met better compared to the national level. We may observe cases though which are imports from other economic regions compared to local transmission (the same problem of course exists on a national level, though the smaller the scale, the more imports 21 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.05.21252520 doi: medRxiv preprint we expect). However, the economic regions represent well-defined regions where we expect a lot of mixing within and less mixing across regions. The estimates of the transmission fitness advantage for the economic regions are largely in line with the national estimates, though of course with larger uncertainty. Two of the regions (Ticino, Central Switzerland) have too little data to make precise statements. Geneva is estimated to be around 1-2 weeks ahead in the B.1.1.7 dynamics compared to Switzerland as a whole. One explanation may be a large number of UK travelers in ski resorts in the Valais in December 2020.

We characterized 4.9% of all confirmed cases over our study period through whole genome sequencing. Our sequencing efforts will continue on a weekly basis with all data being submitted to GISAID. These efforts, where we aim to sequence a random subset of cases throughout Switzerland, are envisioned to facilitate the global tracking of SARS-CoV-2, to allow monitoring the spread of known VoCs, and to enable rapid identification of new VoCs. Such whole genome sequencing efforts are complemented by Swiss-wide VoC-specific tracing efforts [8] . In particular, in the Dr Risch medical laboratories, samples are checked for S dropouts and screened for the 501Y mutation. If a VoC is suspected based on these analyses, whole genome sequencing is performed. In that way, we enrich our whole genome dataset, yielding to an overall characterization of 11.5% of all confirmed cases.

Overall we see consistent signal for a large transmission advantage of B.1.1.7 in Switzerland. This confirms estimates from studies from the UK [1, 2, 3], Denmark [3] , and Switzerland ( [10] ; looking at 501Y mutations). In February, the epidemic appears to have slowed down overall. This may be due to effects of changes in measures on 18.01.2021 and improvement in compliance and adherence. Our core plots are available on [11] and [12] for real-time monitoring. Further, we will add new Variants of Concern to our webpage once they spread in Switzerland. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.05.21252520 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 9, 2021. introductions and transmissions in Switzerland from beginning of October 2020 to February 2021 -implementation of Swiss-wide diagnostic screening and whole genome sequencing. medRxiv, page 2021.02.11.21251589, February 2021.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.05.21252520 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.05.21252520 doi: medRxiv preprint

KJ: Formal analysis, Validation; CA: Methodology, Writing -review & editing; NB: Conceptualization, Funding acquisition, Project administration, Supervision, Writing -review & editing; MA: Conceptualization, Investigation, Writing -review & editing; TS: Conceptualization, Funding acquisition, Investigation, Methodology, Project administration, Supervision, Validation, Writing -original draft

The COVID

Transmission of SARS-CoV-2

1.1.7 in England: Insights from linking epidemiological and genetic data. medRxiv, page 2020.12

Early transmissibility assessment of the n501y mutant strains of sars-cov-2 in the united kingdom

Estimated transmissibility and severity of novel sars-cov-2 variant of concern 202012/01 in england

and on behalf of COVID-19 Genomics Consortium UK (CoG-UK). Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations

Nervtag meeting on sars-cov-2 variant under investigation vui-202012/01

Public health england -investigation of novel sars-cov-2 variant: Variant of concern 202012/01

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

Emergence and spread of a SARS-CoV-2 variant through Europe in the summer of 2020

Transmission of sars-cov-2 variants in switzerland

Sars-cov-2 variants of concern in switzerland

Sars-cov-2 variants of concern in switzerland

github repository for "quantification of the spread of sars-cov-2 variant b.1.1.7 in switzerland

The origin and early spread of sars-cov-2 in europe

Artic v3 multiplex pcr amplicon protocol

Health 2030 genome center github

V-pipe: a computational pipeline for assessing viral genetic diversity from high-throughput data

Sars-cov-2 outbreak in a tri-national urban area is dominated by a b. 1 lineage variant linked to mass gathering events

On measuring selection in experimental evolution

statsmodels: Econometric and statistical modeling with python

Estimation and worldwide monitoring of the effective reproductive number of SARS-CoV-2. medRxiv

A New Framework and Software to Estimate Time-Varying Reproduction Numbers During Epidemics

Coronavirus: Federal council extends and tightens measures

Real-time estimates of the reproductive number for sars-cov-2

We thank Richard Neher for useful discussions on the maximum likelihood inference.